FDA expands indication for TAVR to low-risk patients

Data pix.

ST. LOUIS - a new FDA ruling is expected to have a positive impact on many heart patients. The transcatheter aortic (aye-or-tick) valve implantation, was only available for high-risk patients allowing them to avoid open-heart surgery. Now the FDA ruling now allows the device for low-risk patients too.

Dr. Michael Lim Cardiologist with SLUCare and SSM Health Saint Louis University Hospital discusses how the device works and how the FDA ruling is a game-changer.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.